MMV and sanofi-aventis have have joined forces to conduct the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixed-dose combination of artesunate and amodiaquine, commenced in Côte d’Ivoire in October 2009.